

# Laurie S Conklin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6932736/publications.pdf>

Version: 2024-02-01

27  
papers

929  
citations

687363

13  
h-index

752698

20  
g-index

27  
all docs

27  
docs citations

27  
times ranked

1830  
citing authors

#	ARTICLE	IF	CITATIONS
1	Early Inflammatory Markers are Associated With Inadequate Post-Induction Infliximab Trough in Pediatric Crohn's Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2021, 72, 410-416.	1.8	3
2	Designing clinical trials in paediatric inflammatory bowel diseases: a PIBDnet commentary. <i>Gut</i> , 2020, 69, 32-41.	12.1	37
3	Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study. <i>PLoS Medicine</i> , 2020, 17, e1003222.	8.4	41
4	Serum miRNAs Are Pharmacodynamic Biomarkers Associated With Therapeutic Response in Pediatric Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1597-1606.	1.9	27
5	Exposure-Response Analysis of Vamorolone (VBP15) in Boys With Duchenne Muscular Dystrophy. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 1385-1396.	2.0	8
6	Serum biomarkers associated with baseline clinical severity in young steroid-naïve Duchenne muscular dystrophy boys. <i>Human Molecular Genetics</i> , 2020, 29, 2481-2495.	2.9	19
7	Title is missing!. , 2020, 17, e1003222.		0
8	Title is missing!. , 2020, 17, e1003222.		0
9	Title is missing!. , 2020, 17, e1003222.		0
10	Title is missing!. , 2020, 17, e1003222.		0
11	Title is missing!. , 2020, 17, e1003222.		0
12	Title is missing!. , 2020, 17, e1003222.		0
13	Pediatric Inflammatory Bowel Disease Clinical Innovations Meeting of the Crohn's & Colitis Foundation: Charting the Future of Pediatric IBD. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 27-32.	1.9	8
14	Therapeutics for Inflammatory Bowel Diseases in Children and Adolescents: A Focus on Biologics and an Individualized Treatment Paradigm. <i>Handbook of Experimental Pharmacology</i> , 2019, 261, 363-375.	1.8	4
15	Developmental Pharmacodynamics and Modeling in Pediatric Drug Development. <i>Journal of Clinical Pharmacology</i> , 2019, 59, S87-S94.	2.0	13
16	Population Pharmacokinetics of Vamorolone (VBP15) in Healthy Men and Boys With Duchenne Muscular Dystrophy. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 979-988.	2.0	11
17	Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function. <i>Neurology</i> , 2019, 93, e1312-e1323.	1.1	64
18	Serum biomarkers of glucocorticoid response and safety in anti-neutrophil cytoplasmic antibody-associated vasculitis and juvenile dermatomyositis. <i>Steroids</i> , 2018, 140, 159-166.	1.8	24

#	ARTICLE	IF	CITATIONS
19	Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug. <i>Pharmacological Research</i> , 2018, 136, 140-150.	7.1	69
20	VBP15, a novel dissociative steroid compound, reduces NF $\kappa$ B-induced expression of inflammatory cytokines in vitro and symptoms of murine trinitrobenzene sulfonic acid-induced colitis. <i>Inflammation Research</i> , 2016, 65, 737-743.	4.0	14
21	Identification of Pathway-Specific Serum Biomarkers of Response to Glucocorticoid and Infliximab Treatment in Children with Inflammatory Bowel Disease. <i>Clinical and Translational Gastroenterology</i> , 2016, 7, e192.	2.5	46
22	Serum pharmacodynamic biomarkers for chronic corticosteroid treatment of children. <i>Scientific Reports</i> , 2016, 6, 31727.	3.3	40
23	Detergent Pod Ingestions in Young Children. <i>Clinical Pediatrics</i> , 2014, 53, 1091-1093.	0.8	5
24	Interleukin-10 Receptor Signaling in Innate Immune Cells Regulates Mucosal Immune Tolerance and Anti-Inflammatory Macrophage Function. <i>Immunity</i> , 2014, 40, 706-719.	14.3	455
25	O-022 Ylâ€fInnate Immune IL10 Receptor Signaling Regulates Mucosal Homeostasis and the Function of Anti-inflammatory Macrophages. <i>Inflammatory Bowel Diseases</i> , 2013, 19, S14-S15.	1.9	0
26	Rash induced by anti-tumor necrosis factor agents in an adolescent with Crohn's disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2010, 7, 174-177.	17.8	16
27	Nutritional considerations in pediatric inflammatory bowel disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2010, 4, 305-317.	3.0	25